Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 101

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 101
---
 of two main components:

| ✓ | An mRNA molecule, a fragile single strand polymer                                 
 of nucleic acid that instructs the host cells to produce predetermined protein(s) |

| ✓ | A lipid nanoparticles (LNPs) coating that enables         
 an efficient delivery of nucleic acids into living cells. |

<div align='center'>62</div>

Upon injection these vaccines into the muscle,
the mRNA in the vaccine is taken up by muscle cells and muscle immune cells that start producing the desired protein and displaying it
to specialized immune cells. Despite of wide vaccination with the newly introduced mRNA vaccines, since 2020, the rapid evolution and
spread of new Covid variants have caused severe illnesses and national lockdowns, proving to the world how critical it is to prepare for
future potential pandemics.

Mutations of other dangerous viruses that are
easily transferred from animals to humans, such as bird flu, can erupt at any moment, bringing the global healthcare system to the brink
of collapse, as well as triggering a social and economic crisis similar to what occurred during Covid. New mutations of known deadly viral
diseases, such as Ebola, can pose a rapid and aggressive threat to the entire world.

Novel Approach: LPLT by LipoVation

LipoVation’s team has been focusing
on the development of Liposomal Protein-Loaded Technology (LPLT): a novel immunization platform which can be instrumental in developing
novel vaccines for a variety of serious viral diseases, including Coronavirus, West Nile Virus, Zika, HIV and others. The novel vaccine
platform is expected to cover a wider range of antigens, not just the spike protein, making the vaccine potentially more effective and
more potent in protecting from dangerous mutations.

Subject to the completion of an animal study
currently being performed in Israel under the auspices of Prof. Yehezkel Barenholz at the Hebrew University of Jerusalem, which was to
have been completed in the first quarter of 2025, we shall make a final determination as to the commercial viability of maintaining the
research and development into the immunization platform. The delay in the pre-clinical animal (mice) study currently being conducted
by Prof Barenholz of the Hebrew University in Jerusalem, which was to have been completed in the first quarter of 2025, has prevented
management from receiving important additional information respecting commercial viability (and additional potential IP protection) that
could be available for the vaccine project. The description below is prem